WORCESTER, Mass. Generex Biotechnology Corp. will be among the companies exhibiting at an upcoming American Diabetes Association meeting, Generex said Tuesday.
The company said it would participate at the ADA’s 70th Scientific Sessions in Orlando, Fla., between Friday and next Tuesday. The investigational oral insulin spray Oral-lyn, currently in phase 3 trials, will be showcased at Generex’s booth. The device resembles an asthma inhaler but does not allow the insulin to enter the lungs, instead allowing it to be absorbed through the mouth.
“Insulin has been used for nearly 82 years and consequently has an excellent safety profile unlike the many new drugs that now have 15-year follow-up minimums due to the recent and unfortunate cardiac events affecting many of their patients,” Generex president and CEO Anna Gluskin said in a statement.